Loading...

Unical Partners Calapharm For Genetic Modification As Work Commences On Ultra Modern Medical Center

Unical VC Prof. Zana Akpagu (L) with the Manger of Calapharm Farhan Khan 
The University of Calabar, Unical has signed agreement with Cross River State Pharmaceutical Company, Calapharm for genetic modification research and development.

The agreement was reached on Tuesday,  July 12 during a visit of the Manager of the company,  Mr. Farhan Ahmad Khan to the Vice Chancellor of the University,  Prof. Zana Akpagu.

Khan, a Pakistan Pharmaceutical Consultant to Cross River State government explained that the deal will help Unical to genetically modify Artemisia Annua for local production.

He said the partnership will involve the University of Agriculture Faisalabad, Pakistan and Anamed International EV as research partners for genetic modification and cultivation of medicinal plant, Artemisia Annual in Nigeria.

The Vice-Chancellor, while reacting expressed gratitude to Khan for the opportunity to extend the frontiers of research in genetic modification by making Unical a centre of excellence in this regard.

While promising to mobilize all the stakeholders concerned to get involved in the deal, Akpagu added that the collaboration would be approved in principle and that a meeting of the various departments involved would be convened immediately to begin full-scale negotiations.

In another development, the contractor handling the Ultra-modern Unical Medical Centre, TABUCHIPAT, has promised to deliver the project as soon as possible.

The VC on inspecttion visit with TABUCHIPAT MD, Mr. Pat O'Brien 
Managing Director of the firm, Mr. Pat O'Brien conducted the Vice-Chancellor round the site on Wednesday to inspect men and equipments that have been mobilized to site.

O'Brien assured that they have taken the coordinates and are preparing the site for surveys and construction.
Prof Zana Akpagu 3473281271089376900

Post a comment

emo-but-icon

Home item

Follow by Email

Popular Posts

Contact Us

Name

Email *

Message *